var data={"title":"Raloxifene: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Raloxifene: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6895?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=raloxifene-patient-drug-information\" class=\"drug drug_patient\">see &quot;Raloxifene: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709396\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased risk of venous thromboembolism (VTE):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Increased risk of deep vein thrombosis and pulmonary embolism have been reported with raloxifene. Women with active VTE or a history of VTE should not take raloxifene.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular disease: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Increased risk of death caused by stroke occurred in a trial in postmenopausal women with documented coronary heart disease or increased risk for major coronary reactions. Consider the risk-benefit balance in women at risk for stroke.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673709\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Evista</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217083\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Raloxifene;</li>\n      <li>Apo-Raloxifene;</li>\n      <li>Evista;</li>\n      <li>PMS-Raloxifene;</li>\n      <li>Teva-Raloxifene</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217113\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Selective Estrogen Receptor Modulator (SERM)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217087\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Osteoporosis:</b> Females: Oral: 60 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Risk reduction for invasive breast cancer:</b> Females (postmenopausal): Oral: 60 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Duration of therapy for breast cancer risk reduction:</i> 5 years; may be used longer than 5 years in women with osteoporosis where breast cancer risk reduction is a secondary benefit (Visvanathan 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217088\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9219197\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">CrCl &le;50 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217089\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673710\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evista: 60 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217046\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7885625\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088593.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlVhvYsc7EvEoBY1Oxvw10oQ==&amp;TOPIC_ID=9593\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088593.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930855\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">May be administered at any time of day without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104572\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217062\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis:</b> Treatment and prevention of osteoporosis in postmenopausal women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Risk reduction for invasive breast cancer:</b> Risk reduction of invasive breast cancer in postmenopausal women with osteoporosis; risk reduction of invasive breast cancer in postmenopausal women with high risk for invasive breast cancer (high risk is defined as at least 1 breast biopsy showing lobular carcinoma in situ or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer 1.66% or more [based on the modified Gail model]; factors included in the modified Gail model include current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity, or age of first live birth).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Raloxifene does not eliminate the risk of breast cancer; patients should have a breast exam and mammogram prior to initiating raloxifene and continue regular breast exams and mammograms as per current guideline recommendations. Raloxifene is not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence. Raloxifene is not indicated for the reduction of the risk of noninvasive breast cancer. There are no data available regarding the effect of raloxifene on invasive breast cancer incidence in women with inherited mutations BRCA1, BRCA2 to be able to make specific recommendations on the effectiveness of raloxifene.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217119\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Evista may be confused with AVINza, Eovist</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Raloxifene may be confused with ospemifene, toremifene</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217053\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (3% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (8% to 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (11% to 16%), leg cramps (&le;12%), muscle spasm (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (14% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (3%), syncope (&lt;2%), venous thromboembolism (1% to 2%; includes deep vein thrombosis, pulmonary embolism, retinal vein thrombosis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (6%), hypoesthesia (&lt;2%), neuralgia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (6%), diaphoresis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (7%), vomiting (5%), gastrointestinal disease (3%), flatulence (2% to 3%), gastroenteritis (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal hemorrhage (3% to 6%), mastalgia (4%), leukorrhea (3%), urinary tract abnormality (3%), uterine disease (3%), endometrium disease (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (8%), tendon disease (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (10%), sinusitis (10%), pharyngitis (8%), pneumonia (3%), laryngitis (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cerebrovascular accident, decreased LDL cholesterol (Delmas 1997; Walsh 1998), decreased serum cholesterol (Delmas 1997; Walsh 1998), decreased serum fibrinogen (Walsh 1998), hypertriglyceridemia (in women with a history of increased triglycerides in response to oral estrogens), retinal vein occlusion, superficial thrombophlebitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217065\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of or current venous thromboembolic disorders (including deep vein thrombosis [DVT], pulmonary embolism [PE], and retinal vein thrombosis); pregnancy or women who could become pregnant; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217050\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Raloxifene may increase the risk for DVT and PE; use is contraindicated in patients with history of or current venous thromboembolic disorders</b> (including DVT, PE, or retinal vein thrombosis). Consider risks versus benefits in women at risk for thromboembolism (heart failure [HF], superficial thrombophlebitis, active malignancy). The risk for DVT and PE are higher during the first 4 months of treatment. Superficial thrombophlebitis has also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Breast cancer history: The use of raloxifene has not been adequately studied in women with a prior history of breast cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: <b>[US Boxed Warning]: The risk of death due to stroke is increased in postmenopausal women with coronary heart disease or at increased risk for major coronary events; consider risks versus benefits in women at risk for stroke.</b> Do not use for primary or secondary prevention of cardiovascular disease. Assess risks versus benefits in women at risk for stroke (eg, prior stroke, TIA, atrial fibrillation, hypertension, or smokers).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; safety and efficacy have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertriglyceridemia: Women with a history of marked elevated triglycerides (&gt;5.6 mmol/L or &gt;500 mg/dL) in response to treatment with oral estrogens (or estrogen/progestin) may also develop elevated triglycerides when treated with raloxifene; monitor triglycerides.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment; safety and efficacy have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Uterine bleeding: Investigate unexplained uterine bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Estrogens: Concurrent use with systemic estrogen therapy is not recommended; safety has not been established. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Males: Safety and efficacy have not been established in men. Raloxifene is not indicated for use in men.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Premenopausal women: Safety has not been established in premenopausal women; use in premenopausal women is not indicated and not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Raloxifene does not eliminate the risk of breast cancer; investigate unexplained breast abnormality that occurs during treatment. Raloxifene is not indicated for treatment of invasive breast cancer, to reduce the risk of recurrence of invasive breast cancer, or to reduce the risk of noninvasive breast cancer. The efficacy (for breast cancer risk reduction) in women with inherited BRCA1 and BRCA1 mutations has not been established. The American Society of Clinical Oncology (ASCO) guidelines for breast cancer risk reduction (Visvanathan 2013) recommend raloxifene (for 5 years) as an option to reduce the risk of ER-positive invasive breast cancer in postmenopausal women with a 5-year projected risk (based on NCI trial model) of &ge;1.66%, or with lobular carcinoma in situ. Raloxifene should not be used in premenopausal women. Women with osteoporosis may use raloxifene beyond 5 years of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged immobilization: Discontinue raloxifene at least 72 hours prior to and during prolonged immobilization (postoperative recovery or prolonged bed rest); restart only once patient fully ambulatory. Advise patients to move periodically during prolonged travel.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299977\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217055\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9593&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Raloxifene.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Raloxifene may decrease the absorption of Levothyroxine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. Selective Estrogen Receptor Modulators may diminish the therapeutic effect of Ospemifene. Ospemifene may also diminish the therapeutic effects of other Selective Estrogen Receptor Modulators. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217056\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217069\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in in animal reproduction studies. Raloxifene is contraindicated for use in women who are or may become pregnant. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548218\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if raloxifene is excreted into breast milk. Breast-feeding is contraindicated by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930854\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Osteoporosis prevention or treatment: Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Women and men should consume:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Calcium: 1,000 mg/day (men: 50 to 70 years) <b>or</b> 1,200 mg/day (women &ge;51 years and men &ge;71 years) (IOM 2011; NOF [Cosman 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: 800 to 1,000 int. units daily (men and women &ge;50 years) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 int. units daily (men and women &le;70 years) <b>or</b> 800 int. units daily (men and women &ge;71 years) (IOM 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217058\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Lipid profile (in women at risk for hypertriglyceridemia); mammogram and breast exam (prior to and regularly during treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteoporosis: Bone mineral density (BMD) should be evaluated 1 to 2 years after initiating therapy and every 2 years thereafter (NOF [Cosman 2014]); annual measurements of height and weight; serum calcium and 25(OH)D; may consider monitoring biochemical markers of bone turnover</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21303306\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium (total): Adults: 9 to 11 mg/dL (2.05 to 2.54 mmol/L), may slightly decrease with aging</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use; however, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM 2011): Sufficient levels in practically all persons: &ge;20 ng/mL (50 nmol/L); concern for risk of toxicity: &gt;50 ng/mL (125 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteoporosis patients (NOF [Cosman 2014]): Recommended level to reach and maintain: ~30 ng/mL (75 nmol/L) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217049\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Raloxifene is an estrogen agonist/antagonist (a selective estrogen receptor modulator [SERM]); selective binding activates estrogenic pathways in some tissues and antagonizes estrogenic pathways in other tissues. Raloxifene acts like an estrogen agonist in the bone to prevent bone loss and has estrogen antagonist activity to block some estrogen effects in the breast and uterine tissues. Raloxifene decreases bone resorption, increasing bone mineral density and decreasing fracture incidence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217064\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid; ~60% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 2,348 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Highly protein bound (95% to albumin and &alpha;-glycoprotein); does not bind to sex-hormone-binding globulin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, extensive first-pass metabolism; metabolized to glucuronide conjugates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~2% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 27.7 hours (following a single dose); 32.5 hours (following multiple doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (primarily); urine (&lt;0.2% as unchanged drug; &lt;6% as glucuronide conjugates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217068\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Evista Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $792.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Raloxifene HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $213.84</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217070\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alofix (BD);</li>\n      <li>Bonmax (IN);</li>\n      <li>Celvista (TH);</li>\n      <li>Evifyne (AU);</li>\n      <li>Evista (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HR, HU, ID, IE, IL, IT, JO, KE, KR, KW, LB, LK, LR, LT, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PE, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, TN, TR, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Larfen (PH);</li>\n      <li>Loxar (UY);</li>\n      <li>Optruma (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FR, GB, GR, HN, IE, IT, LT, MT, NL, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>Opturma (HR);</li>\n      <li>Ostiral (TR);</li>\n      <li>Oxilar (BD);</li>\n      <li>Prelox (BD);</li>\n      <li>Ralox (BD, VN);</li>\n      <li>Raloxiqueen (KR);</li>\n      <li>Raxeto (AR);</li>\n      <li>Rolage (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barrett-Connor E, Mosca L, Collins P, et al, &ldquo;Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women,&rdquo; <i> N Engl J Med</i>, 2006, 355(2):125-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/16837676/pubmed\" target=\"_blank\" id=\"16837676\">16837676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delmas PD, Bjarnason NH, Mitlak BH, et al, &ldquo;Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women,&rdquo; <i>N Engl J Med</i>, 1997, 337(23):1641-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/9385122/pubmed\" target=\"_blank\" id=\"9385122\">9385122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Draper MW, Flowers DE, Huster WJ, et al, &ldquo;A Controlled Trial of Raloxifene (LY139481) HCl: Impact on Bone Turnover and Serum Lipid Profile in Healthy Postmenopausal Women,&rdquo; <i>J Bone Miner Res</i>, 1996, 11(6):835-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/8725181/pubmed\" target=\"_blank\" id=\"8725181\">8725181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evista (raloxifene) [prescribing information]. Indianapolis, IN: Eli Lilly and Co; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Land SR, Wickerham DL, Costantino JP, et al, &ldquo;Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial,&rdquo; <i>JAMA</i>, 2006, 295(23):2742-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/16754728/pubmed\" target=\"_blank\" id=\"16754728\">16754728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martino S, Cauley JA, Barrett-Connor E, et al, &ldquo;Continuing Outcomes Relevant to Evista: Breast Cancer Incident in Postmenopausal Women in a Randomized Trial of Raloxifene,&rdquo; <i>J Natl Cancer Inst</i>, 2004, 96(23):1751-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/15572757/pubmed\" target=\"_blank\" id=\"15572757\">15572757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raloxifene [prescribing information]. Mason, OH: Prasco Laboratories; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siris ES, Harrris ST, Eastell R, et al, &ldquo;Skeletal Effects of Raloxifene After 8 Years: Results From the Continuing Outcomes Relevant to Evista (CORE) Study,&rdquo; <i>J Bone Miner Res</i>, 2005, 20(9):1514-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/16059623/pubmed\" target=\"_blank\" id=\"16059623\">16059623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2013;31(23):2942-2962.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/23835710/pubmed\" target=\"_blank\" id=\"23835710\">23835710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vogel VG, Costantino JP, Wickerham DL, &ldquo;Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial,&rdquo; <i>JAMA</i>, 2006, 295(23):2727-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/16754727/pubmed\" target=\"_blank\" id=\"16754727\">16754727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. <i>JAMA</i>. 1998;279(18):1445-1451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/9600478/pubmed\" target=\"_blank\" id=\"9600478\">9600478</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9593 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709396\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24673709\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F217083\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F217113\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F217087\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F217088\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9219197\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F217089\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24673710\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F217046\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7885625\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2930855\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104572\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F217062\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F217119\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F217053\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F217065\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F217050\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299977\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F217055\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F217056\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F217069\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20548218\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2930854\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F217058\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F21303306\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F217049\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F217064\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F217068\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F217070\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9593|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=raloxifene-patient-drug-information\" class=\"drug drug_patient\">Raloxifene: Patient drug information</a></li></ul></div></div>","javascript":null}